Zerbaxa is a combination of ceftolozan, a novel cephalosporin, and tazobactam, a beta-lactamase inhibitor.
Zerbaxa is specifically indicated for the treatment of patients 18 years or older with the following infections caused by designated susceptible microorganisms:
Complicated intra-abdominal infections
- Zerbaxa used in combination with metronidazole is indicated for the treatment of complicated intra-abdominal infections caused by the following Gram-negative and Gram-positive microorganisms:Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, and Streptococcus salivarius.
Complicated Urinary Tract Infections, including Pyelonephritis
- Zerbaxa is indicated for the treatment of complicated urinary tract infections including pyelonephritis, caused by the following Gram-negative microorganisms: Escherichiacoli, Klebsiella pneumoniae, Proteus mirabilis, and Pseudomonas aeruginosa.
Submit your review
Adverse effects associated with the use of Zerbaxa may include, but are not limited to, the following:
The recommended dosage regimen of Zerbaxa (ceftolozane/tazobactam) for Injection is 1.5 g (1 g/0.5 g) administered every 8 hours by intravenous infusion over 1 hour in patients 18 years or older and with normal renal function or mild renal impairment. The duration of therapy should be guided by the severity and site of infection and the patient’s clinical and bacteriological progress.